Loading
Every dated change on the records linked to Primary CNS lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Complete remission 49 percent with MATRix (methotrexate, cytarabine, thiotepa, rituximab) against 23 percent with methotrexate-cytarabine alone; two-year failure-free survival 76 percent after whole-brain radiotherapy and 75 percent after autologous transplant.
Adding rituximab and thiotepa to methotrexate-cytarabine improves response and survival.